Cargando…
Reprogrammed CD4(+) T Cells That Express FoxP3(+) Control Inhibitory Antibody Formation in Hemophilia A Mice
Coagulation Factor VIII (FVIII) replacement therapy in hemophilia A patients is complicated by the development of inhibitory antibodies, which often render the treatment ineffective. Previous studies demonstrated a strong correlation between induction of regulatory T cells (Treg) and tolerance to th...
Autores principales: | Herzog, Roland W., Kuteyeva, Veronica, Saboungi, Rania, Terhorst, Cox, Biswas, Moanaro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391332/ https://www.ncbi.nlm.nih.gov/pubmed/30842776 http://dx.doi.org/10.3389/fimmu.2019.00274 |
Ejemplares similares
-
Ex vivo expanded autologous polyclonal regulatory T cells suppress inhibitor formation in hemophilia
por: Sarkar, Debalina, et al.
Publicado: (2014) -
Treg: tolerance vs immunity
por: Biswas, Moanaro, et al.
Publicado: (2015) -
Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A
por: Sherman, Alexandra, et al.
Publicado: (2017) -
Gene Therapy With Regulatory T Cells: A Beneficial Alliance
por: Biswas, Moanaro, et al.
Publicado: (2018) -
Immune Modulatory Cell Therapy for Hemophilia B Based on CD20-Targeted Lentiviral Gene Transfer to Primary B Cells
por: Wang, Xiaomei, et al.
Publicado: (2017)